WDR62 has been reported to be overexpressed in multiple cancers and closely associated with tumor development, including bladder cancer [23], lung adenocarcinoma [24], prostate cancer [25], gastric cancer [26], colorectal cancer [27–28], and hepatocellular carcinoma [29], where it promotes tumor malignancy and correlates with a poor patient prognosis. The gene discussed is WDR62; the disease is prostate carcinoma.